Difficulty: Medium
Average Score: 89%
Testbank
A patient who was diagnosed with Parkinsons disease several months ago recently began treatment with levodopa-carbidopa. The patient and his family are excited that he has experienced significant symptom relief. The nurse should be aware of what implication of the patients medication regimen?
Correct answer
D
Rationale
Benefits of levodopa-carbidopa often diminish after 1 or 2 years of treatment.
This option is accurate as patients with Parkinson's disease may initially respond well to levodopa-carbidopa, but over time, the effectiveness can decline, leading to a need for dosage adjustments or alternative therapies. Understanding this is crucial for the nurse in managing the patient’s long-term care and expectations.
A: The patient is in a honeymoon period when adverse effects of levodopa-carbidopa are not yet evident. This option misinterprets the nature of the treatment response; while some patients may experience an initial improvement, the diminishing benefits are not simply a matter of adverse effects being absent.
B: Benefits of levodopa-carbidopa do not peak until 6 to 9 months after the initiation of treatment. This statement is misleading, as most patients notice symptom relief within weeks of starting treatment, not after several months, which contradicts the patient's immediate positive response.
C: The patient's temporary improvement in status is likely unrelated to levodopa-carbidopa. This option incorrectly dismisses the known therapeutic effects of levodopa-carbidopa, as the significant symptom relief experienced by the patient is directly associated with the medication's action in managing Parkinson's disease symptoms.
This option is accurate as patients with Parkinson's disease may initially respond well to levodopa-carbidopa, but over time, the effectiveness can decline, leading to a need for dosage adjustments or alternative therapies. Understanding this is crucial for the nurse in managing the patient’s long-term care and expectations.
A: The patient is in a honeymoon period when adverse effects of levodopa-carbidopa are not yet evident. This option misinterprets the nature of the treatment response; while some patients may experience an initial improvement, the diminishing benefits are not simply a matter of adverse effects being absent.
B: Benefits of levodopa-carbidopa do not peak until 6 to 9 months after the initiation of treatment. This statement is misleading, as most patients notice symptom relief within weeks of starting treatment, not after several months, which contradicts the patient's immediate positive response.
C: The patient's temporary improvement in status is likely unrelated to levodopa-carbidopa. This option incorrectly dismisses the known therapeutic effects of levodopa-carbidopa, as the significant symptom relief experienced by the patient is directly associated with the medication's action in managing Parkinson's disease symptoms.